Study guide
15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup
Key Takeaways Explain This Topic AI
Endometrial biopsy is mandatory for any patient 45 or older with abnormal uterine bleeding, and under 45 with unopposed estrogen exposure, obesity, PCOS, failed therapy, or persistent bleeding.
Hormonal therapy must never be started in those high-risk groups before tissue histology excludes atypical hyperplasia and adenocarcinoma.
Primary amenorrhea is absence of menses by age 15 with normal secondary sexual characteristics, or by age 13 with none.
Breasts present with absent uterus distinguishes Mullerian agenesis, which has normal pubic hair and female testosterone, from androgen insensitivity syndrome, which has absent pubic hair and male-range testosterone.
Breasts absent with a uterus present and elevated FSH indicates hypergonadotropic hypogonadism such as Turner syndrome, while low or normal FSH indicates hypothalamic or pituitary failure.
Last updated: September 2026
- Diagnostic Evaluation Algorithm for AUB Diagnostic Evaluation Algorithm for Reproductive-Age AUB
- ├── 1. Mandatory First Step: Sensitive Urine or Serum hCG (Rule out Pregnancy!)
- ├── 2. History & Physical: Vitals, Hemodynamic stability, Speculum & Bimanual Exam
- ├── 3. Core Laboratory Panel
- │ ├── Complete Blood Count (CBC) with Platelets (Assess anemia & thrombocytopenia)
- │ ├── Ferritin (Detect occult iron deficiency without overt anemia)
- │ ├── Thyroid-Stimulating Hormone (TSH) & Serum Prolactin
- │ ├── Cervical NAAT Screening (Chlamydia/Gonorrhea) & Pap cytology (if due)
- │ └── Targeted Coagulation Panel (if AUB-C screening criteria positive)
- ├── 4. First-Line Pelvic Imaging: Transvaginal Ultrasound (TVUS) ± Saline Infusion (SIS)
- │ └── Evaluate endometrial stripe thickness, myometrial architecture, focal lesions
- └── 5. Histological Tissue Sampling: Endometrial Biopsy (EMB)
- ├── Age ≥45 years with AUB
- └── Age <45 years with high-risk factors (unopposed estrogen, obesity BMI ≥30,
- PCOS, failed medical therapy, or persistent bleeding)
[!CRITICAL] AMCB Board Rule on Endometrial Biopsy Indications: An in-office endometrial biopsy (EMB) is non-negotiable for any patient aged 45 or older presenting with AUB , and for any patient under 45 with chronic unopposed estrogen exposure (e.g., obesity BMI ≥30 kg/m², PCOS), prolonged amenorrhea, failed medical management, or persistent abnormal bleeding . Never start hormonal therapy in these high-risk cohorts without first obtaining tissue histology to exclude endometrial adenocarcinoma and atypical hyperplasia!
Amenorrhea Workup: Primary vs. Secondary
Amenorrhea is broadly classified into primary and secondary variants, each requiring distinct diagnostic pathways.
Primary Amenorrhea
Defined clinically as:
Absence of menses by age 15 years in an individual with normal growth and normal female secondary sexual characteristics (e.g., breast budding / thelarche). Or,
Absence of menses by age 13 years in an individual with complete absence of secondary sexual characteristics (no breast development). Primary Amenorrhea Etiological Triage
- ├── Breasts Present, Uterus Absent (Normal Thelarche, Anatomic Defect)
- │ ├── 1. Müllerian Agenesis (MRKH Syndrome, 46,XX)
- │ │ └── Normal ovaries, normal female testosterone, normal pubic/axillary hair
- │ └── 2. Androgen Insensitivity Syndrome (AIS, 46,XY)
- │ └── Cryptorchid testes, elevated adult male testosterone, absent pubic/axillary hair
- ├── Breasts Present, Uterus Present (Intact Anatomy, Outflow Obstruction or Endocrine)
- │ ├── Imperforate Hymen / Transverse Vaginal Septum (Cyclic pain, hematocolpos, bulging membrane)
- │ └── Secondary Amenorrhea Etiologies (PCOS, Hyperprolactinemia, Hypothalamic)
- ├── Breasts Absent, Uterus Present (Hypogonadism / Estrogen Deficiency)
- │ ├── Hypergonadotropic Hypogonadism (Elevated FSH/LH >30–40 mIU/mL)
- │ │ └── Turner Syndrome (45,XO gonadal dysgenesis, streak gonads, webbed neck, short stature)
- │ └── Hypogonadotropic Hypogonadism (Low/Normal FSH/LH)
- │ └── Hypothalamic failure (Kallmann syndrome with anosmia, severe malnutrition/stress)
- └── Breasts Absent, Uterus Absent (Extremely rare: 17,20-desmolase deficiency)
- Secondary Amenorrhea
Defined clinically as the absence of menses for ≥3 consecutive months in an individual with previously regular menstrual cycles, OR ≥6 consecutive months in an individual with previously irregular menstrual cycles.
Stepwise Secondary Amenorrhea Cascade
Rule Out Pregnancy: Order a sensitive serum or urine hCG . Pregnancy is the single most common cause of secondary amenorrhea in reproductive-age individuals.
Initial Biochemical Triage: Simultaneously evaluate TSH , Serum Prolactin , and FSH/Estradiol .
Elevated TSH: Hypothyroidism increases thyrotropin-releasing hormone (TRH), which directly stimulates anterior pituitary lactotrophs, producing secondary hyperprolactinemia and anovulation.
Elevated Prolactin (>25–30 ng/mL): Repeat fasting prolactin. Hyperprolactinemia suppresses pulsatile hypothalamic GnRH secretion. If sustained, perform contrast-enhanced pituitary MRI to evaluate for pituitary adenoma (prolactinoma).
Elevated FSH (>30–40 mIU/mL) on two occasions drawn 4–6 weeks apart: Diagnostic of Premature Ovarian Insufficiency (POI) in individuals <40 years of age.
Low or Inappropriately Normal FSH and LH with low Estradiol: Diagnostic of Functional Hypothalamic Amenorrhea (FHA) secondary to eating disorders, intense athletic training, psychological stress, or chronic systemic illness.
The Progestin Challenge Test (Progesterone Withdrawal Challenge):
Administer Medroxyprogesterone Acetate (MPA) 10 mg PO daily for 10 days (or micronized progesterone 200 mg daily for 10 days).
Positive Withdrawal Bleeding (bleeding occurs within 2 to 7 days of completing the regimen): Confirms (a) an anatomically intact and patent outflow tract (cervix, vagina, uterus), (b) adequate endogenous circulating estrogen that has primed and proliferated the endometrium, and (c) anovulation as the definitive etiology (most frequently PCOS).
Negative Test (no withdrawal bleeding): Indicates either (a) severe hypoestrogenism (endometrium was never primed/proliferated) OR (b) an anatomical outflow tract obstruction or scarred, obliterated endometrium ( Asherman syndrome from prior aggressive curettage or infection).
Estrogen-Progestin Challenge Test:
If the progestin challenge is negative, administer oral micronized 17β-estradiol 2 mg daily for 21 days , adding MPA 10 mg daily for the final 10 days (Days 12–21).
Bleeding Occurs: Proves the endometrium is capable of proliferating and the outflow tract is patent. The underlying cause is profound hypoestrogenism (FHA or ovarian failure).
No Bleeding Occurs: Confirms an irreversible anatomical outflow tract defect or endometrial synechiae ( Asherman syndrome ); diagnostic hysteroscopy is indicated.